ROYAL GLOBE LTD

Dengue Vaccine: Dengvaxia (CYD-TDV)
Description: Dengvaxia is the world’s first dengue vaccine, designed to protect against all four dengue virus serotypes. It is indicated for individuals aged 9 to 45 who have had a previous dengue infection. By offering up to 80% protection, Dengvaxia significantly reduces the incidence of dengue fever, dengue hemorrhagic fever, and related hospitalizations. Targeted for endemic regions, this vaccine is crucial for public health initiatives aiming to control dengue outbreaks.

Key Benefits:

Reduces the risk of severe dengue by up to 93%
Approved for use in multiple countries
Supports community health and tourism in endemic areas